Contract facts
FederalNo full NAICS 325411 intel page yet. Browse NAICS intelligence
4558177645!DOXYCYCLINE HYCLATE 100 MG VLS is a federal award for Dla Troop Support held by Hikma Pharmaceuticals Usa Inc. Estimated value $153K ($153K obligated). Current period of performance ends Aug 24, 2022. Place of performance: BERKELEY HEIGHTS NJ.
4558177645!DOXYCYCLINE HYCLATE 100 MG VLS
Recompete timing
PublicCurrent PoP ended Aug 24, 2022 (1458 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2D322F427G?
SPE2D322F427G (4558177645!doxycycline hyclate 100 MG VLS) is a Dla Troop Support award with a potential value of $153K, currently held by Hikma Pharmaceuticals Usa Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2D322F427G?
Dla Troop Support awarded SPE2D322F427G to Hikma Pharmaceuticals Usa Inc (potential $153K).
Who is the incumbent on SPE2D322F427G?
Hikma Pharmaceuticals Usa Inc is the incumbent. The current period of performance ends Aug 24, 2022.
When does Hikma Pharmaceuticals Usa Inc’s SPE2D322F427G come up for recompete?
SCOUT tracks a period-of-performance end of Aug 24, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.